HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Hari, P. [1 ]
Lin, H. M. [2 ]
Zhu, Y. [2 ]
Berg, D. [2 ]
Richardson, P. [3 ]
Moreau, P. [4 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Millennium Pharmaceut Inc, Cambridge, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Hosp Hotel Dieu, Nantes, France
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P735
引用
收藏
页码：297 / 298
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
    Neeraj Gupta
    Yeow Tee Goh
    Chang-Ki Min
    Jae Hoon Lee
    Kihyun Kim
    Raymond S. M. Wong
    Chor Sang Chim
    Michael J. Hanley
    Huyuan Yang
    Karthik Venkatakrishnan
    Ai-Min Hui
    Dixie-Lee Esseltine
    Wee Joo Chng
    Journal of Hematology & Oncology, 8
  • [32] PHASE 1 PHARMACOKINETIC (PK) STUDY OF IXAZOMIB CITRATE (MLN9708) PLUS LENALIDOMIDE AND DEXAMETHASONE IN ASIAN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Gupta, N.
    Goh, Y. T.
    Min, C. K.
    Lee, J. H.
    Suh, C.
    Kim, K.
    Wong, R.
    Chim, J.
    Hanley, M. J.
    Yang, H.
    Venkatakrishnan, K.
    Hui, A. M.
    Schusterbauer, C.
    Chng, W. J.
    HAEMATOLOGICA, 2014, 99 : 372 - 372
  • [33] Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.
    Mateos, Maria-Victoria
    Masszi, Tamas
    Grzasko, Norbert
    Hansson, Markus
    Sandhu, Irwindeep
    Pour, Ludek
    Viterbo, Luisa
    Jackson, Sharon R.
    Stoppa, Anne-Marie
    Gimsing, Peter
    Hamadani, Mehdi
    Borsaru, Gabriela
    Berg, Deborah
    Lin, Jianchang
    Van De Velde, Helgi
    Richardson, Paul G.
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)
    Moreau, Philippe
    Masszi, Tunas
    Grzasko, Norbert
    Bahlis, Nizar J.
    Hansson, Markus
    Pour, Ludek
    Sandhu, Irwindeep
    Ganly, Peter
    Baker, Bartrum W.
    Jackson, Sharon
    Stoppa, Anne -Marie
    Simpson, David R.
    Gimsing, Peter
    Palumbo, Antonio
    Garderet, Laurent
    Cavo, Michele
    Kumar, Shaji K.
    Touzeau, Cyrille
    Buadi, Francis
    Laubach, Jacob P.
    Lin, Jianchang
    Berg, Deborah
    DiBacco, Alessandra
    Hui, Ai -Min
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [35] Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
    San-Miguel, Jesus F.
    Hungria, Vania T. M.
    Yoon, Sung-Soo
    Beksac, Meral
    Dimopoulos, Meletios Athanasios
    Elghandour, Ashraf
    Jedrzejczak, Wieslaw Wiktor
    Guenther, Andreas
    Nakorn, Thanyaphong Na
    Siritanaratkul, Noppadol
    Corradini, Paolo
    Chuncharunee, Suporn
    Lee, Je-Jung
    Schlossman, Robert L.
    Shelekhova, Tatiana
    Yong, Kwee
    Tan, Daryl
    Numbenjapon, Tontanai
    Cavenagh, Jamie D.
    Hou, Jian
    LeBlanc, Richard
    Nahi, Hareth
    Qiu, Lugui
    Salwender, Hans
    Pulini, Stefano
    Moreau, Philippe
    Warzocha, Krzysztof
    White, Darrell
    Blade, Joan
    Chen, WenMing
    de la Rubia, Javier
    Gimsing, Peter
    Lonial, Sagar
    Kaufman, Jonathan L.
    Ocio, Enrique M.
    Veskovski, Ljupco
    Sohn, Sang Kyun
    Wang, Ming-Chung
    Lee, Jae Hoon
    Einsele, Hermann
    Sopala, Monika
    Corrado, Claudia
    Bengoudifa, Bourras-Rezki
    Binlich, Florence
    Richardson, Paul G.
    LANCET ONCOLOGY, 2014, 15 (11): : 1195 - 1206
  • [36] Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010).
    Dimopoulos, MA
    Spencer, A
    Attal, M
    Prince, M
    Harousseau, JL
    Dmoszynska, A
    Yu, ZU
    Olesnyckyj, M
    Zeldis, J
    Knight, R
    BLOOD, 2005, 106 (11) : 6A - 7A
  • [37] Ixazomib plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (RRMM) patients in real-world experience: a pooled analysis from the INSIGHT MM observational study and the Czech Registry of Monoclonal Gammopathies (RMG)
    Weisel, K.
    Hajek, R.
    Terpos, E.
    Lee, H. C.
    Chari, A.
    Costello, C. L.
    Puig, N.
    Leleu, X.
    Berdeja, J. G.
    Davies, F. E.
    Usmani, S. Z.
    Hungria, V. T. M.
    Boccadoro, M.
    Rifkin, R. M.
    Zonder, J. A.
    Cook, G.
    Brozova, L.
    Barinova, M.
    Ren, K.
    Skacel, T.
    Stull, D. M.
    Maisnar, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 125 - 125
  • [38] A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma
    Salles, Gilles
    Shah, Harsh
    Leonard, John P.
    Szanto, Attila
    Chen, Jade
    Bannerji, Rajat
    Morschhauser, Franck
    Nastoupil, Loretta J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S454 - S455
  • [39] A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
    Martin, Thomas
    Baz, Rachid
    Benson, Don M.
    Lendvai, Nikoletta
    Wolf, Jeffrey
    Munster, Pamela
    Lesokhin, Alexander M.
    Wack, Claudine
    Charpentier, Eric
    Campana, Frank
    Vij, Ravi
    BLOOD, 2017, 129 (25) : 3294 - 3303
  • [40] A randomized phase 3 trial of oral lenalidomide and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Final analysis of MM010 study
    Anagnostopoulos, A.
    Dimopoulos, M. A.
    Spencer, A.
    Attal, M.
    Prince, M.
    Harousseau, J.-L.
    Dmoszynska, A.
    San Miguel, J.
    Hellmann, A.
    Facon, T.
    Foa, R.
    Lazzarino, M.
    Masliak, Z.
    Olesnyckyj, M.
    Yu, Z.
    Patin, J.
    Zeldis, J. B.
    Knight, R. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 171 - 172
12345